Bexion Pharmaceuticals to Present at BIO Convention 2024

Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on novel biologic therapies for solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), has announced its participation in the 2024 Biotechnology Innovation Organization (BIO) International Convention. The event is scheduled to take place from June 3-6, 2024, in San Diego, California.

Presentation Details:
- Location: Theater 1, Hall A, Exhibition Hall
- Session Date and Time: Wednesday, June 5 at 11:15 am PT

Scott Shively, CEO of Bexion, expressed excitement about participating in the convention. He highlighted the company's progress in their clinical programs for metastatic colorectal cancer (mCRC) and CIPN, emphasizing the critical milestones they are approaching.

For those interested in scheduling a meeting with Bexion at the convention, requests can be made through the BIO One-on-One Partnering™ platform. Additional details about the event can be found on the BIO International Convention 2024 website.

The BIO International Convention is recognized as the largest and most comprehensive event in the biotechnology sector, attracting over 20,000 industry leaders globally. The convention covers a wide array of topics, including therapeutic advancements, biotech business strategies, regulatory and policy developments, and human resources in the industry.

BXQ-350 is the lead drug candidate from Bexion Pharmaceuticals. It is a first-in-class biologic that features the multifunctional sphingolipid activator protein, Saposin C, combined with a phospholipid. BXQ-350 has shown promising preclinical antitumor effects both in vitro and in vivo, especially in colorectal, brain, and other solid tumors. Two Phase 1 clinical trials, one involving adults and another with pediatric patients suffering from diffuse intrinsic pontine glioma (DIPG), have confirmed BXQ-350's safety and indicated single-agent activity across multiple solid tumors. Additionally, other clinical and preclinical studies suggest that BXQ-350 might be effective in treating chemotherapy-induced peripheral neuropathy.

Bexion Pharmaceuticals is committed to developing innovative biologic therapies to address solid tumor cancers and CIPN, with the potential to expand its portfolio into other cancer types and broader neuropathic pain indications. The company currently has three clinical trials open for enrollment, advancing its mission to bring new therapeutic options to patients in need.